Business
Total Voting Rights
Total Voting Rights.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 7759A Evgen Pharma PLC 02 January 2018 \n\n \n\n\n\n\n \n\n\n \n\n\n\n\n2 January 2018\n\n\n \n\n\n\n\n \n \n \n \n \n \nEvgen Pharma plc \n \n (\"Evgen Pharma\" or \"the Company\")\n \nTotal Voting Rights \n \nEvgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, makes the following notification in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1.\nAs at 29 December 2017 the Company's issued share capital consists of 93,276,858 Ordinary Shares of 0.25p each.\nThe total number of voting rights in the Company is 93,276,858 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.\n \nEnquiries\n\n\n\n\nEvgen Pharma plc\nDr Stephen Franklin, CEO\nRichard Moulson, CFO\nwww.evgen.com\n\n\nc/o +44 (0) 20 7466 5000\n \n\n\n\n\n\n\n\n\n\n\n\n\nBuchanan\nMark Court, Sophie Wills, Stephanie Watson\n\n\n+44 (0) 20 7466 5000\n \n\n\n\n\n\n\n\n\n\n\n\n\nNorthland Capital Partners Limited\nMatthew Johnson, Gerry Beaney (Corporate Finance)\nJohn Howes, Rob Rees (Corporate Broking)\n\n\n+44 (0) 20 3861 6625\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nNotes for editors\nAbout Evgen Pharma plc\nEvgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. \nEvgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. \nFor further information, please visit: www.evgen.com\nFor commissioned research on the Company, pleas...